These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 3280000)

  • 1. Low-dose cyclosporin A in severe psoriasis. A double-blind study.
    Van Joost T; Bos JD; Heule F; Meinardi MM
    Br J Dermatol; 1988 Feb; 118(2):183-90. PubMed ID: 3280000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
    Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
    Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of side-effects of medium- and low-dose cyclosporin maintenance therapy in psoriasis.
    de Rie MA; Meinardi MM; Bos JD
    Br J Dermatol; 1990 Sep; 123(3):347-53. PubMed ID: 2206973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies.
    Timonen P; Friend D; Abeywickrama K; Laburte C; von Graffenried B; Feutren G
    Br J Dermatol; 1990 Jun; 122 Suppl 36():33-9. PubMed ID: 2196082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term use of cyclosporin A in severe psoriasis.
    Van Joost T; Heule F; Stolz E; Beukers R
    Br J Dermatol; 1986 May; 114(5):615-20. PubMed ID: 3718852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results of cyclosporin treatment of severe, chronic psoriasis vulgaris].
    Engst R; Huber J
    Hautarzt; 1989 Aug; 40(8):486-9. PubMed ID: 2676910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis.
    Laburte C; Grossman R; Abi-Rached J; Abeywickrama KH; Dubertret L
    Br J Dermatol; 1994 Mar; 130(3):366-75. PubMed ID: 8148280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four years of experience with cyclosporin A for psoriasis.
    Powles AV; Baker BS; Valdimarsson H; Hulme B; Fry L
    Br J Dermatol; 1990 Jun; 122 Suppl 36():13-9. PubMed ID: 2369568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal side effects of high and low cyclosporin A doses in patients with rheumatoid arthritis.
    Berg KJ; Førre O; Djøseland O; Mikkelsen M; Narverud J; Rugstad HE
    Clin Nephrol; 1989 May; 31(5):232-8. PubMed ID: 2661065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function and blood pressure in psoriatic patients treated with cyclosporin A.
    Feutren G; Abeywickrama K; Friend D; von Graffenried B
    Br J Dermatol; 1990 Jun; 122 Suppl 36():57-69. PubMed ID: 2196085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of PUVA- and retinoid-PUVA-resistant severe psoriasis with systemic cyclosporin A.
    Takashima A; Morita A; Tsuji T
    J Dermatol; 1990 Aug; 17(8):482-8. PubMed ID: 2229652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherlands.
    Meinardi MM; de Rie MA; Bos JD
    Br J Dermatol; 1990 Jun; 122 Suppl 36():27-31. PubMed ID: 2196081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cyclosporin for psoriasis.
    Griffiths CE; Powles AV; McFadden J; Baker BS; Valdimarsson H; Fry L
    Br J Dermatol; 1989 Feb; 120(2):253-60. PubMed ID: 2923798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function after long-term low-dose cyclosporin for psoriasis.
    Powles AV; Carmichael D; Hulme B; Thomas E; McFadden J; Baker B; Valdimarsson H; Fry L
    Br J Dermatol; 1990 May; 122(5):665-9. PubMed ID: 2112945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy.
    Korstanje MJ; Bilo HJ; Stoof TJ
    Br J Dermatol; 1992 Nov; 127(5):501-4. PubMed ID: 1467290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.
    Maza A; Montaudié H; Sbidian E; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP; Paul C
    J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():19-27. PubMed ID: 21388455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney biopsies in control or cyclosporin A-treated psoriatic patients. International Kidney Biopsy Registry of Cyclosporin A (Sandimmun) in Autoimmune Diseases.
    Br J Dermatol; 1990 Jun; 122 Suppl 36():95-100. PubMed ID: 2369573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial.
    Reitamo S; Spuls P; Sassolas B; Lahfa M; Claudy A; Griffiths CE;
    Br J Dermatol; 2001 Sep; 145(3):438-45. PubMed ID: 11531834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
    Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.